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 Abstract 
 
Objectives  
This secondary analysis of data from a RCT explores associations between 
common symptom clusters and evaluates pre to post-treatment changes in 
clinical levels of these symptoms following Cognitive Behaviour Therapy for 
insomnia (CBT-I).  
 
Methods  
Baseline data from 113 participants with insomnia were explored to establish 
rates of and associations between clinical levels of fatigue, anxiety and 
depression across the sample. Effects of CBT-I on this symptom cluster was 
also explored by examining changes in pre to post fatigue, anxiety and 
depression levels.  
 
Results  
At baseline, the most common symptom presentation was insomnia+fatigue 
and 30% of the sample reported at least three co-morbid symptoms. Post 
CBT, those experiencing clinical insomnia and clinical fatigue decreased. 
There were no changes in anxiety rates from baseline to post-treatment in the 
CBT group, and modest reductions in rates of those with clinical depression. 
Seven individuals (9.6%) from the CBT group were completely symptom-free 
at post-treatment compared with 0% from the TAU condition. Chi-square 
analysis revealed a significant relationship between group allocation and 
changes in symptoms of insomnia and fatigue. No such relationship was 
found between group allocation and mood variables.  
 
Conclusions  
These findings confirm the high rate of symptom co-morbidities among cancer 
patients and highlight strong associations between sleep and fatigue. CBT for 
insomnia appears to offer generalised benefit to the symptom cluster as a 
whole and specifically, is effective in reducing fatigue, which exceeded clinical 
cut-offs prior to implementation of the intervention. This has implications for 
the diagnosis/management of common symptoms in cancer patients. 
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 Introduction 
 
Disturbed sleep is a common and distressing problem affecting more 
than one-third of cancer patients both during and after completion of active 
treatment 1,2. Despite its prevalence, insomnia is frequently rationalised as a 
transient side-effect of diagnosis-related stress or cancer treatment 3-5. 
Incidence data show however, that more than one quarter of cancer patients 
with sleep disturbance experience chronic insomnia, which fails to remit even 
when active cancer treatment has ceased 4.  
Sleep disturbance is often associated with other symptoms like fatigue, 
anxiety and depression 5-9. Portenoy et. al. demonstrated that this cluster was 
highly prevalent (40-80%) across different tumour types 10, and recent work by 
Liu et al. found that the presence of pre-treatment symptom clusters in breast 
cancer patients was associated with poorer sleep, increased fatigue and lower 
mood during active treatment 11. Therefore each symptom seems to maintain 
and exacerbate the others, resulting in further impairment to quality of life.  
Such inter-relationships have also been studied in the general 
population. For example, psychiatric epidemiology indicates that insomnia is 
an independent risk factor for the development of first episode depressive 
disorder in adults of all ages 12. Similarly, people with cancer and insomnia 
report decreased functioning, more pain and higher levels of fatigue than 
those sleeping well 13,14. Sharma et al. 15 found that nearly a third of patients 
attending a Regional Cancer Centre reported sleep problems of clinical 
significance which were strongly associated with symptoms of emotional 
distress. The nature of these associations requires further study. 
Implementing a programme of Cognitive Behaviour Therapy for 
insomnia (CBT-I) in cancer patients yields generalised improvements in other 
symptoms including fatigue, quality of life and daytime functioning 16,17, 
suggesting that these symptoms share common pathways 8,18,19.  
The aims of this paper are: (i) to report on the rates of and associations 
between co-morbid clinical symptoms of insomnia, fatigue, anxiety and 
depression in a sample of cancer patients, (ii) to investigate potential 
generalised effects on these symptoms following CBT-I and (iii) to assess the 
clinical significance of any such improvement.  
 
Methods 
Experimental Design 
This is a secondary analysis of data from 113 patients, derived from a 
randomised controlled clinical effectiveness trial of CBT-I versus treatment as 
usual (TAU) for insomnia in cancer patients 16. CBT comprised five, small 
group sessions across consecutive weeks, following a manualised protocol.  
TAU represented normal clinical practice; the appropriate control for a clinical 
effectiveness study. The trial conformed to a pragmatic, two-centre design 
comparing CBT-I with TAU. Major assessments were at baseline, post-
treatment and follow-up 6 months later (6-month assessment is not reported 
due to missing data). Suitable participants were randomly allocated to either 
CBT-I or TAU by means of a centralised computer-based 
registration/randomisation service available within the Cancer Research UK 
Clinical Trials Unit, Glasgow. The study was stratified for centre, existing 
treatment for insomnia and tumour type using the minimisation method. A 2:1 
treatment allocation, in favour of the intervention, was selected because this 
would make more efficient use of available CBT-I sessions and would 
minimise the time a patient had to wait before being able to start a CBT-I 
course, thereby reducing patient dropout.  Due to the nature of the 
intervention, it was not possible to blind participants or therapists to allocation. 
No adverse events were reported with either CBT-I or TAU. Full details of 
CBT therapists, integrity-fidelity of treatment allocation and attrition rates are 
provided in the attached Consort diagram or can be found in Espie et al. 
(2008)16.  
 
Recruitment of Participants 
Participants (18 yr.+) were attending follow-up oncology clinics at either 
the Glasgow Beatson Oncology Centre (BOC) or Aberdeen Royal Infirmary 
(ARI). Included participants had been diagnosed with either breast, prostate, 
bowel, or gynaecological cancer and had satisfied diagnostic criteria for 
chronic insomnia, defined as mean value > 30 minutes for the complaint of 
delayed sleep-onset latency (SOL) and/or wake time after sleep onset 
(WASO), insomnia occurring 3 or more nights per week for at least 3 months 
and affecting daytime function 20,21. Participants had also scored 5 or more on 
the Pittsburgh Sleep Quality Index (PSQI) 22,23, a psychometrically robust 
instrument that identifies clinically significant sleep disturbance. Thus acute 
insomnia and transient side-effects associated with cancer treatment were 
excluded. Participants had completed anti-cancer therapy (radiotherapy/ 
FKHPRWKHUDS\E\PRQWKDQGKDGQRIXUWKHUDQWL-cancer therapy planned 
(excepting adjuvant hormone therapy for breast and prostate patients). 
Participants were excluded if they had acute illness, estimated prognosis <6 
months, another sleep disorder, confusional problems or untreated and 
unstable psychiatric disorder (screening procedures did not identify anyone 
with untreated/unstable psychiatric disorder so therefore, no-one was 
excluded on the basis of their psychiatric history). 
Potential participants were notified of the study by posters/leaflets in 
clinic waiting areas, by mailing information to those attending upcoming clinics 
or directly by staff upon attendance at clinics. All participants provided written 
informed consent and their medical consultant agreed to their participation. 
The protocol was approved by local NHS research ethics committees.  
 
Insert Table I 
 
Measures 
We conducted a secondary analysis of sleep-onset latency (SOL) and 
wake time after sleep onset (WASO), anxiety and depression and fatigue 
(severity and interference), using a ten day Sleep Diary 24, the Hospital 
Anxiety and Depression Scale (HADS) 25 and the Fatigue Symptom Inventory 
(FSI) 26.  
Sleep diaries are the staple tool of insomnia assessment practice and 
offer a valid, relative index of sleep disturbance when used as repeated 
measures.27 Participants were trained to complete sleep diaries using 
established criteria for accurate completion 28.  The HADS has been validated 
for use in cancer patients to screen for anxiety and depressive symptoms 29,30. 
It is a particularly useful measure for assessing mood in sleep research, as 
unlike many other anxiety/depression questionnaires, the HADS does not 
contain a sleep-specific item. The FSI is also recommended for use with 
cancer patients, as a brief measure with good validity and internal consistency 
26,31. Median values for these scales (and subscales) are presented in Table I.   
In order to understand poly-symptomatic associations between 
insomnia and clinical level symptoms of fatigue, anxiety and depression, 
baseline data were re-analysed to isolate only those participants scoring 
beyond recognised clinical cut-offs for insomnia and at least one other 
domain. Therefore, µDQ[LHW\¶ UHIHUs to HADS DQ[LHW\ VFRUHV RI   29,30, 
µGHSUession¶UHIHUs to HADS GHSUHVVLRQVFRUHVRI29,30 and µIDWLJXH¶UHIHUs 
WRIDWLJXHVHYHULW\DQGRULQWHUIHUHQFHVFRUHVRI on the FSI 31,32. Applying 
these criteria1  to the data meant that 37 participants, who were included in 
the analyses for the original trial, were excluded from this secondary analysis. 
This means that the proportions presented in the results section relates only 
to patients who presented with comorbidity at baseline. 
Statistical methods 
The RCT was designed to have 80% power to detect a standardized 
difference of 0.5 between the treatments in the primary sleep outcome 
measures at post-treatment. A significance level of 0.0125 was chosen to 
                                                 
1
 In order to enhance the validity of our results, we opted to use a cut-off of 11 on the HADS. 
We acknowledge that this potentially reduces the possibility of identifying clinical cases of depression 
and anxiety and therefore, higher rates of comorbidity. However, we feel that the integrity of our results 
is enhanced by applying more rigorous criteria to the diagnosis of clinical mood symptoms. 
 
adjust for multiple comparisons. These criteria implied recruiting 204 
participants. In practice, slow recruitment meant that a total of 150 patients 
were randomly assigned, giving 80% power to detect a slightly larger 
standardized difference of 0.59.  
 
Results 
 
Descriptive analysis of baseline data across the entire sample (n=113) 
showed that alongside clinical levels of insomnia, 76 participants (67%) also 
reported levels of fatigue that reached or exceeded clinical cut-offs. This was 
the most common symptom profile. The next most common presentation was 
µinsomnia + fatigue + anxiety¶, reported by 20 individuals (18% of the total 
sample). 6 participants (5%) scored above clinical cut-offs for all symptoms 
DQG µinsomnia + fatigue + GHSUHVVLRQ¶DOVRDFFRXQWHGIRU% of the sample. 
The least common symptom presentDWLRQV ZHUH µinsomnia + DQ[LHW\¶ (3 
participants)µinsomnia + anxiety + GHSUHVVLRQ¶ (2 participants) DQGµinsomnia 
+ depression¶DFFRXQWLQJIRU% and 0% of the sample respectively. 
 
Insert Figure I 
 
 In order to explore whether CBT had any effect on the presence or 
absence of clinical level symptoms between baseline and post treatment, the 
percentage of individuals who met clinical cut-offs for each symptom was 
calculated. The number of people experiencing clinical level insomnia at post 
treatment was reduced by 52% in the CBT group, compared with a 17.5% 
reduction in TAU. The rate of clinical levels of fatigue was extremely high 
across both treatment arms at baseline (90.4% CBT, 90% TAU). However, 
CBT-I resulted in a 10.9% reduction in rates of fatigue compared with a 2.5% 
increase in at post treatment in the TAU group. There was no change in 
anxiety rates from baseline to post treatment in the CBT group, and a 5% 
increase in those with anxiety at post treatment in the TAU group. The 
majority of participants were not depressed at baseline (90.4% CBT, 92.5% 
TAU) and CBT reduced the rate of those with clinical levels of depression by 
5.5% compared with an increase of 5% in TAU. Importantly, 7 individuals 
(9.6%) from the CBT group were completely symptom-free at post treatment 
(compared to 0% in TAU). Further inspection of baseline data from this 
µV\PSWRP-IUHH¶ JURXS VKRZ WKDW DOO  LQGLYLGXDOV KDG ERWK FOLQLFDO OHYHO
insomnia and clinical level fatigue. No one had clinical level anxiety but 1 
person had clinical level depression. Although this group is small, the pattern 
of symptom change indicates that CBT may be of some benefit when treating 
clinical level insomnia and fatigue.  
 
Insert Table II 
 
 Change data (baseline to post treatment) were calculated for each of 
the four variables of interest, in order to compare differences in symptom 
trajectories (symptom remission vs. maintenance of baseline presentation) 
between treatment arms. ,Q WKLV FDVH µV\PSWRP UHPLVVLRQ¶ UHIHUV WR WKH
presence of a symptom exceeding clinical cut-offs at baseline which is then 
below this cut-off at post treatment. µ0DLQWHQDQFH¶UHIHUVWRHLWKHUDV\PSWRP
exceeding clinical cut-offs at baseline which is still beyond this cut-off at post 
treatment, or a symptom below clinical cut-offs at baseline which is still below 
this cut-off at post treatment.  
Insomnia 
 At post treatment, 52% of the CBT group showed insomnia remission, 
compared with only 17.5% of the TAU group. Chi-square analyses were 
conducted to test the significance of this µsymptom trajectory*group allocation¶ 
relationship. Results show that there was a significant association between 
treatment group allocation and post-treatment change in insomnia symptoms 
[X2(1, N=113) = 12.875, p<0.001].  
 
Fatigue 
 17.4% of the CBT group showed fatigue remission at post treatment, 
compared with 2.6% of TAU group. Fatigue symptoms were maintained in 
82.6% of the CBT group and 97.4% of the TAU group. Chi-square analysis 
confirms a significant association between treatment group allocation and 
post-treatment change in fatigue [X2(1, N=107) = 5.002, p=0.03] (using 
Fishers exact test). 
Anxiety 
 Anxiety remission at post treatment was noted in 5.8% (CBT) and 5.6% 
(TAU) of cases respectively. The majority of both groups maintained their 
baseline anxiety scores at post treatment (94.2% CBT, 94.4% TAU). No 
significant associations were found between treatment allocation and anxiety 
symptom change [X2(1, N=105) = 0.003, p=1.00] (using Fishers exact test). 
Depression 
 8.5% of the CBT group showed depression remission at post 
treatment, compared with 0% of the TAU group. As with anxiety, the majority 
of those in the CBT group (91.5%), maintained their baseline depression 
scores at post treatment (compared with 100% of the TAU group). No 
significant associations were found between treatment allocation and 
depression symptom change [X2(1, N=109) = 3.398, p=0.09] (using Fishers 
exact test). 
 Overall, we can conclude that there is a significant relationship 
between group allocation (i.e. CBT or TAU) and changes in clinical levels of 
insomnia and fatigue. No such relationship was found between group 
allocation and mood variables. 
Worsening of symptoms 
Whilst calculating change score data from the CBT group, we 
discovered that in a small number of cases, symptoms seemed to worsen at 
post treatment (characterised by post treatment data exceeding clinical levels 
when baseline data had not). Given that this finding was not isolated to the 
TAU group, we decided to analyse these individuals separately. Given that all 
participants had baseline insomnia scores that exceeded clinical cut-offs, it 
was not possible for insomnia to worsen at post treatment (according to our 
criteria). Also, it is not surprising that insomnia-related symptoms would 
worsen in the TAU group over time. Therefore, only those people with 
worsening symptoms of fatigue, anxiety and depression following CBT is 
examined. Of the 8 people, 4 reported worsening fatigue, 2 reported 
worsening anxiety and 2 reported worsening anxiety + depression.  
 
Discussion 
  All participants in our original trial of CBT versus TAU met criteria for 
clinical insomnia16. However less than a quarter of them (n=37) were troubled 
by sleep problems alone, with the majority (n=113) experiencing other co-
morbid symptoms like fatigue, anxiety and depression. Further analysis of this 
symptom cluster revealed that clinical fatigue was the most common co-
morbid symptom, experienced by the majority of participants at baseline. 
Almost a third of participants in this study presented with three or more co-
existing symptoms which exceeded clinical cut-offs. These findings are 
consistent with previous evidence of the high prevalence of symptom clusters 
in cancer patients 5-9.  
At baseline, anxiety was more prevalent than depression across both 
groups, although the number of participants experiencing clinical levels of 
either symptom was small. Findings from a large prospective study examining 
symptoms in early breast cancer patients over 5 years, also reported higher 
levels of clinically significant anxiety than depression (14.4% vs. 3.1%) 29,30. 
Our data indicates a relatively small association between clinical insomnia 
and mood disturbance, which is in contrast to numerous studies reporting high 
rates of co-morbidity between insomnia and depression and insomnia and 
anxiety in cancer patients 8,9,11,15.  However, the current study applied strict 
clinical cut-offs for identifying those with depression and anxiety which may 
explain this reduced prevalence. Low levels of clinically meaningful anxiety 
and depression in this sample may also be due to the time since diagnosis in 
our sample (median of approximately 2 years), as initially high levels of 
distress after diagnosis and during treatment would be expected to decrease 
over time. Insomnia is commonly viewed as an expected consequence of 
depression or anxiety, but this low insomnia-mood association indicates that 
the majority of participants (67%) in this study experienced chronic insomnia 
without any significant clinical mood disturbance. It is therefore important that 
mood and sleep symptoms are recognised as distinct disorders and 
measured and treated in their own right.    
Our CBT-I intervention, delivered primarily to treat sleep disturbance, 
resulted in a significant reduction in insomnia prevalence at post treatment 
compared to the TAU group. However, further exploration of the data reveals 
that treating insomnia with CBT offers additional benefits to the symptom 
cluster as a whole. Participants receiving CBT-I also experienced significant 
reductions in fatigue, and 10% of the CBT-I group no longer met clinical 
criteria for any symptoms post-treatment.  None of the participants in the TAU 
group were symptom free at post treatment, indeed symptoms often 
worsened in this group at post treatment assessment. This suggests that 
improvements in the CBT-I group did not occur simply as an artefact of 
natural symptom reduction over time, but as a direct result of the intervention.  
The most notable symptom reduction within the CBT-I group were for 
sleep and fatigue symptoms. The CBT-I treatment clearly improved sleep 
symptoms and had some effect on fatigue. It appears that participants were 
more able to manage their fatigue symptoms after receiving the intervention, 
reducing the impact of fatigue on their quality of life. Researchers have begun 
to investigate the interactional relationship between disturbed sleep and 
fatigue in cancer patients5 and further exploration of the shared and individual 
mechanisms of these symptoms for this group would be beneficial. There is 
currently no accepted gold standard treatment for cancer related fatigue 
although psychological and exercise interventions have shown promise 33,34. It 
would be useful to further explore consider the role of CBT interventions in the 
treatment of this sleep + fatigue symptom cluster.  
Although these findings were derived from a relatively large sample of 
cancer patients, we cannot assume that our sample is representative of the 
cancer population as a whole. The majority of our patients were female and 
breast/prostate cancer was the most common tumour type. It is therefore 
difficult to generalise these findings to patients with different tumour types, as 
it is possible that the prevalence of the symptom cluster may differ between 
cancer types. However, these results do provide further evidence of the 
development of and associations between common symptom clusters in this 
patient group and indicate the usefulness of CBT for reducing clinical levels of 
insomnia and fatigue in cancer patients. 
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Table I ± Baseline demographic and clinical information on the sample. Data are categorical 
or median (IR). No between-group differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CBT group 
(n=73) 
 
 
 
TAU group 
(n=40) 
 
Age (years) 
 
63 (55-69) 
 
58 (54-66) 
Gender 
Male 
Female 
 
23 (32%) 
50 (68%) 
 
12 (30%) 
28 (70%) 
Civil status 
Married 
Single 
Separated 
Divorced  
Widowed 
 
51 (70%) 
8 (11%) 
1 (1%) 
7 (10%) 
6 (8%) 
 
27 (68%) 
7 (17%) 
0 
4 (10%) 
2 (5%) 
Employment status 
Employed 
Unemployed  
Retired 
 
27 (37%) 
2 (3%) 
44 (60%) 
 
18 (45%) 
1 (2%) 
21 (53%) 
Tumour site 
Breast 
Prostate 
Bowel 
Gynaecological 
 
46 (63%) 
18 (25%) 
8 (11%) 
1 (1%) 
 
22 (55%) 
9 (23%) 
8 (20%) 
1 (2%) 
Cancer diagnosis - screening 
(months)  
22 (9-52) 25 (10-68) 
Current treatment for depression 
Yes 
No 
 
10 (14%) 
63 (86%) 
 
7 (17%) 
33 (83%) 
Insomnia duration (months)  30 (12-60) 27 (10-60) 
 
 
Table II ± Group allocation * symptom present or absent at baseline (BL) and post treatment 
(PT)  
 
 CBT  
(BL) 
CBT 
(PT) 
TAU 
(BL) 
TAU 
(PT) 
Insomnia 
Absent 
Present 
 
0% 
100% 
 
52% 
48% 
 
0% 
100% 
 
17.5% 
82.5% 
Fatigue 
Absent 
Present 
 
9.6% 
90.4% 
 
20.5% 
79.5% 
 
10% 
90% 
 
7.5% 
92.5% 
Anxiety 
Absent 
Present 
 
79.5% 
20.5% 
 
79.5% 
20.5% 
 
77.5% 
22.5% 
 
72.5% 
27.5% 
Depression 
Absent 
Present 
 
90.4% 
9.6% 
 
95.9% 
4.1% 
 
92.5% 
7.5% 
 
87.5% 
12.5% 
Symptom free 
 
 
0% 
 
9.6% 
 
0% 
 
0% 
 
 
 
Insomnia pattern 
Constant 
Episodic 
 
49 (67%) 
24 (33%) 
 
25 (63%) 
15 (37%) 
Sleep medication 
Yes 
No 
 
18 (25%) 
55 (75%) 
 
6 (15%) 
34 (85%) 
PSQI 13 (11-16) 13 (11-15) 
Sleep 
SOL (mins) 
WASO (mins) 
 
41 (20-59) 
69 (47-118) 
 
27 (23-50) 
47 (30-81) 
Fatigue 
Severity  
Interference 
 
5 (4-6) 
4 (2-5) 
 
5 (4-6) 
4 (2-5) 
Anxiety 7 (4-10) 8 (5-10) 
Depression 4 (2-8) 5 (2-7) 
 Figure I - Venn diagram representing baseline associations between fatigue (F), anxiety (A) 
and depression (D) scores across the sample (n=113).. All participants met criteria for 
insomnia.     
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F  
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